250 related articles for article (PubMed ID: 11156560)
1. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.
Sugidachi A; Asai F; Yoneda K; Iwamura R; Ogawa T; Otsuguro K; Koike H
Br J Pharmacol; 2001 Jan; 132(1):47-54. PubMed ID: 11156560
[TBL] [Abstract][Full Text] [Related]
2. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
[TBL] [Abstract][Full Text] [Related]
5. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors.
Humphries RG; Tomlinson W; Ingall AH; Cage PA; Leff P
Br J Pharmacol; 1994 Nov; 113(3):1057-63. PubMed ID: 7858849
[TBL] [Abstract][Full Text] [Related]
6. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
7. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Sugidachi A; Ogawa T; Kurihara A; Hagihara K; Jakubowski JA; Hashimoto M; Niitsu Y; Asai F
J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
[TBL] [Abstract][Full Text] [Related]
8. Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation.
Vigne P; Hechler B; Gachet C; Breittmayer JP; Frelin C
Biochem Biophys Res Commun; 1999 Mar; 256(1):94-7. PubMed ID: 10066429
[TBL] [Abstract][Full Text] [Related]
9. On the mechanism of plasmin-induced platelet aggregation. Implications of the dual role of granule ADP.
Ishii-Watabe A; Uchida E; Mizuguchi H; Hayakawa T
Biochem Pharmacol; 2000 Jun; 59(11):1345-55. PubMed ID: 10751543
[TBL] [Abstract][Full Text] [Related]
10. Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor.
Takasaki J; Kamohara M; Saito T; Matsumoto M; Matsumoto S; Ohishi T; Soga T; Matsushime H; Furuichi K
Mol Pharmacol; 2001 Sep; 60(3):432-9. PubMed ID: 11502873
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo.
Humphries RG; Tomlinson W; Clegg JA; Ingall AH; Kindon ND; Leff P
Br J Pharmacol; 1995 Jul; 115(6):1110-6. PubMed ID: 7582510
[TBL] [Abstract][Full Text] [Related]
12. Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation.
Roger S; Pawlowski M; Habib A; Jandrot-Perrus M; Rosa JP; Bryckaert M
FEBS Lett; 2004 Jan; 556(1-3):227-35. PubMed ID: 14706855
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors.
Paul BZ; Jin J; Kunapuli SP
J Biol Chem; 1999 Oct; 274(41):29108-14. PubMed ID: 10506165
[TBL] [Abstract][Full Text] [Related]
14. Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats.
Sugidachi A; Yamaguchi S; Jakubowski JA; Ohno K; Tomizawa A; Hashimoto M; Niitsu Y
J Cardiovasc Pharmacol; 2011 Sep; 58(3):329-34. PubMed ID: 21697729
[TBL] [Abstract][Full Text] [Related]
15. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
Frelinger AL; Jakubowski JA; Li Y; Barnard MR; Linden MD; Tarnow I; Fox ML; Sugidachi A; Winters KJ; Furman MI; Michelson AD
J Thromb Haemost; 2008 Feb; 6(2):359-65. PubMed ID: 18021304
[TBL] [Abstract][Full Text] [Related]
16. Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses.
Shankar H; Murugappan S; Kim S; Jin J; Ding Z; Wickman K; Kunapuli SP
Blood; 2004 Sep; 104(5):1335-43. PubMed ID: 15142872
[TBL] [Abstract][Full Text] [Related]
17. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets.
Daniel JL; Dangelmaier C; Jin J; Ashby B; Smith JB; Kunapuli SP
J Biol Chem; 1998 Jan; 273(4):2024-9. PubMed ID: 9442039
[TBL] [Abstract][Full Text] [Related]
19. Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin.
Puri RN; Colman RF; Colman RW
Eur J Biochem; 1996 Mar; 236(3):862-70. PubMed ID: 8665907
[TBL] [Abstract][Full Text] [Related]
20. Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.
Savi P; Laplace MC; Maffrand JP; Herbert JM
J Pharmacol Exp Ther; 1994 May; 269(2):772-7. PubMed ID: 8182545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
